Experimental gene therapy aims to restore sight in rare childhood blindness

NCT ID NCT05878860

First seen May 01, 2026 · Last updated May 01, 2026

Summary

This study tests a new gene therapy called ATSN-201 for people with X-linked retinoschisis, a rare genetic eye disease that causes vision loss. The trial includes children and adults aged 6 and older, and will check if the treatment is safe and can improve vision. The therapy works by delivering a working copy of the RS1 gene to the retina.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED RETINOSCHISIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bascom Palmer Eye Institute

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

  • Children's Hospital of Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

    Contact

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

  • Oregon Health Sciences University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact

Conditions

Explore the condition pages connected to this study.